Arvind J Trindade1, Petros C Benias1, Sumant Inamdar1, Cathy Fan2, Amrita Sethi3, Norio Fukami4, Allon Kahn4, Michel Kahaleh5, Iman Andalib5, Divyesh V Sejpal1, Arvind Rishi2. 1. Division of Gastroenterology, Zucker School of Medicine at Hofstra/Northwell, Long Island Jewish Medical Center, New Hyde Park, NY, USA. 2. Department of Pathology, Long Island Jewish Medical Center, New Hyde Park, NY, USA. 3. Columbia University Medical Center, Division of Gastroenterology, New York, NY, USA. 4. Division of Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ, USA. 5. Department of Gastroenterology, Weill Cornell Medical College, New York, NY, USA.
Abstract
BACKGROUND: Accurate staging of superficial esophageal squamous cell cancer (ESCC) for endoscopic therapy is challenging. Optical coherence tomography (OCT) has been shown to be superior to high-resolution endoscopic ultrasound (EUS). Volumetric Laser Endomicroscopy (VLE), a second-generation OCT, has recently become commercially available. OBJECTIVE: To assess if VLE can determine which patients with superficial ESSC can undergo endoscopic therapy. METHODS: This is a multi-center retrospective study. Patients were included if (a) they had visible ESCC, (b) they underwent VLE and EUS for staging, and c) if superficial disease was suspected then endoscopic resection had to be performed to have accurate histology to compare the VLE scan to. VLE scans were then compared to the gold standard: histology for superficial disease and EUS for disease T1b and greater. RESULTS: Seventeen patients were included with the following disease: squamous intraepithelial neoplasia (4 patients), T1a disease (6 patients), T1b (2 patients), T2 disease (2 patients) and T3 disease (3 patients). VLE was able to distinguish superficial disease, defined as disease limited up to the lamina propria, from non-superficial disease in all cases. CONCLUSIONS: VLE may be able to determine which ESCC patients are candidates for endoscopic therapy. Prospective studies are needed to confirm this.
BACKGROUND: Accurate staging of superficial esophageal squamous cell cancer (ESCC) for endoscopic therapy is challenging. Optical coherence tomography (OCT) has been shown to be superior to high-resolution endoscopic ultrasound (EUS). Volumetric Laser Endomicroscopy (VLE), a second-generation OCT, has recently become commercially available. OBJECTIVE: To assess if VLE can determine which patients with superficial ESSC can undergo endoscopic therapy. METHODS: This is a multi-center retrospective study. Patients were included if (a) they had visible ESCC, (b) they underwent VLE and EUS for staging, and c) if superficial disease was suspected then endoscopic resection had to be performed to have accurate histology to compare the VLE scan to. VLE scans were then compared to the gold standard: histology for superficial disease and EUS for disease T1b and greater. RESULTS: Seventeen patients were included with the following disease: squamous intraepithelial neoplasia (4 patients), T1a disease (6 patients), T1b (2 patients), T2 disease (2 patients) and T3 disease (3 patients). VLE was able to distinguish superficial disease, defined as disease limited up to the lamina propria, from non-superficial disease in all cases. CONCLUSIONS: VLE may be able to determine which ESCC patients are candidates for endoscopic therapy. Prospective studies are needed to confirm this.
Authors: Jacques J G H M Bergman; Yue-Ming Zhang; Shun He; Bas Weusten; Liyan Xue; David E Fleischer; Ning Lu; Sanford M Dawsey; Gui-Qi Wang Journal: Gastrointest Endosc Date: 2011-08-15 Impact factor: 9.427
Authors: Ryan P Merkow; Karl Y Bilimoria; Rajesh N Keswani; Jeanette Chung; Karen L Sherman; Lawrence M Knab; Mitchell C Posner; David J Bentrem Journal: J Natl Cancer Inst Date: 2014-07-16 Impact factor: 13.506
Authors: Cadman L Leggett; Emmanuel C Gorospe; Daniel K Chan; Prasuna Muppa; Victoria Owens; Thomas C Smyrk; Marlys Anderson; Lori S Lutzke; Guillermo Tearney; Kenneth K Wang Journal: Gastrointest Endosc Date: 2015-09-03 Impact factor: 9.427
Authors: Oscar Caravaca Mora; Philippe Zanne; Lucile Zorn; Florent Nageotte; Natalia Zulina; Sara Gravelyn; Paul Montgomery; Michel de Mathelin; Bernard Dallemagne; Michalina J Gora Journal: Biomed Opt Express Date: 2020-02-03 Impact factor: 3.732